Expert Answers to HCP Questions on CAR T-Cell Therapies in Lymphoma

In this episode, Frederick L. Locke, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with lymphomas, with questions including:How does the recent approval of lisocabtagene maraleucel and the expanded indication for axicabtagene ciloleucel add to the treatment landscape for DLBCL? Do you see CAR T-cell therapy ever being used in the first-line setting for DLBCL?How should physicians select patients for CAR T-cell therapy vs ASCT in DLBCL?How should physicians sequence CAR T-cell therapy vs BTK inhibitors in MCL?Presenter:Frederick L. Locke, MDCo-LeaderMoffitt Immuno-Oncology ProgramVice Chair and Associate Member Department of Blood and Marrow Transplant and Cellular ImmunotherapyResearch Director and Medical DirectorImmune Cell Therapy ProgramMoffitt Cancer CenterTampa, FloridaContent based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma.Link to full program: https://bit.ly/3rDeFCV Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.